Key Highlights

  • Loss per share was USD 4.74 against an estimate of a USD 2.24 loss.
  • Collaboration Revenue was USD 132 thousand against an estimate of USD 1.03 million.
  • Net loss was USD 50.02 million, compared with USD 7.45 million.
  • Cash was USD 57.94 million at September 30, 2026.

Cue Biopharma (NASDAQ:CUE) reported third quarter 2026 collaboration revenue of USD 132 thousand, compared with USD 2.15 million in the prior-year quarter. Collaboration revenue was USD 132 thousand against an estimate of USD 1.03 million.

The net loss was USD 50.02 million, compared with USD 7.45 million. Net loss per share was USD 4.74, compared with USD 2.22, against an estimate of a USD 2.24 loss.

Third Quarter Results

General and administrative expense was USD 29.83 million, compared with USD 4.94 million, and Research and Development expense was USD 17.02 million, compared with USD 4.75 million. Total operating expenses were USD 47.23 million, compared with USD 9.74 million.

The loss from operations was USD 47.10 million, compared with USD 7.60 million. Interest income was USD 483 thousand, and the change in Fair Value of financial instruments was a loss of USD 3.40 million. Weighted average shares outstanding were 10,561,814, compared with 3,362,311.

Nine-Month Results

For the nine months ended September 30, 2026, collaboration revenue was USD 13.70 million, compared with USD 5.52 million, and total operating expenses were USD 153.84 million. The loss on issuance of Liability warrants was USD 90.01 million.

The net loss was USD 208.26 million, compared with USD 28.19 million, and net loss per share was USD 28.70, compared with USD 9.37.

Balance Sheet and Liquidity

Cash was USD 57.94 million at September 30, 2026, compared with USD 27.14 million at December 31, 2025. Total Assets were USD 67.26 million, compared with USD 42.21 million, and total liabilities were USD 28.86 million, compared with USD 15.78 million.

Current liabilities were USD 19.73 million, compared with USD 13.49 million, and net cash used in Operating Activities for the nine months was USD 50.0 million. Shares outstanding were 7,753,995, compared with 3,220,707. The company states that it believes its cash and cash equivalents at September 30, 2026 are sufficient to meet projected operating needs for at least twelve months from the issuance date of the financial statements.

Net cash used in operating activities for the nine months was USD 50.03 million, compared with USD 20.61 million, and net cash used in investing activities was USD 121 thousand, compared with USD 6.95 million. Total current assets were USD 66.71 million, compared with USD 36.98 million.

Total stockholders' Equity was USD 38.40 million, compared with USD 26.43 million, and the accumulated Deficit was USD 576.73 million, compared with USD 368.47 million.

Cue Biopharma Q3 2026 Earnings: Key Takeaways

Cue Biopharma reported third quarter 2026 collaboration revenue of USD 132 thousand and a net loss of USD 50.02 million. Cash was USD 57.94 million at September 30, 2026. Net cash used in operating activities for the nine months was USD 50.03 million, compared with USD 20.61 million.